4
4TEEN4 Pharmaceuticals
Biotech & Life Sciences · Hennigsdorf, Germany · Founded 2002
4TEEN4 Pharmaceuticals develops innovative biomarkers for diagnosis, prediction and monitoring of acute medical conditions MoreLess
4TEEN4 Pharmaceuticals GmbH is a biotechnology company focused on developing innovative treatments for Cardiogenic Shock, a severe condition with high mortality rates primarily affecting patients in intensive care units. The company's flagship product, Procizumab, is a first-in-class inhibitor of the Dipeptidyl Peptidase 3 (DPP3) pathway, designed to restore cardiac function and reduce mortality. Procizumab has shown clinical proof of concept and represents a breakthrough in an area with no effective therapies currently available.
4TEEN4 Pharmaceuticals operates in the healthcare and pharmaceutical markets, targeting hospitals and medical institutions that treat acute myocardial injuries and related conditions. The company generates revenue through the development and potential commercialization of its proprietary drug, Procizumab.
Supported by funding from the European Social Fund (ESF) and the Federal State of Brandenburg, 4TEEN4 Pharmaceuticals is committed to advancing medical science and improving patient outcomes. The company employs a team of dedicated scientists and innovators, working in a dynamic small-to-medium enterprise (SME) environment.
Keywords: Cardiogenic Shock, Procizumab, DPP3 inhibitor, biotechnology, clinical proof, cardiac function, high mortality, intensive care, myocardial injuries, pharmaceutical innovation.
Company overview
4TEEN4 Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2002
- Headquarters
- Hennigsdorf, Germany
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 79.2
Valuation & funding
4TEEN4 Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Mar 2026 | $0 | — | Christ Capital | ↗ |
| SERIES COther financing | Nov 2025 | $61M | $242M | Undisclosed | ↗ |
| EARLY VCOther financing | Feb 2025 | $0 | — | Görlich-Gruppe | — |
| EARLY VCOther financing | Oct 2024 | $0 | — | Brandenburg Kapital · FLORA Ventures · Carpian · Therabel Pharma | — |
| EARLY VCOther financing | Feb 2024 | $0 | — | Undisclosed | — |
| FundingOther financing | Aug 2020 | Undisclosed | — | ||
| SERIES AOther financing | Dec 2019 | Brandenburg Kapital | ↗ | ||
| EARLY VCOther financing | Oct 2018 | Wellington Partners · HBM Partners | ↗ | ||
| EARLY VCOther financing | Jun 2018 | Brandenburg Kapital | — | ||
| GRANTOther financing | Apr 2015 | European Commission | — |
Growth signals
4TEEN4 Pharmaceuticals website traffic
Latest recorded traffic for 4TEEN4 Pharmaceuticals is 1.1K monthly website visits, up 1000% over the last three months. 4TEEN4 Pharmaceuticals's team grew 5.7% over the past year.
Hiring
Open positions at 4TEEN4 Pharmaceuticals
Current openings linked to this company in Dealroom.
Comparisons
4TEEN4 Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
4TEEN4 Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Investors
20 investors on 4TEEN4 Pharmaceuticals's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where 4TEEN4 Pharmaceuticals has talent and traffic
team presence
In the news
Latest news about 4TEEN4 Pharmaceuticals
Recent press, funding announcements, and product moves mentioning 4TEEN4 Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about 4TEEN4 Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about 4TEEN4 Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See 4TEEN4 Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.